Harmony Biosciences Holdings (HRMY) Non-Current Debt (2019 - 2026)

Harmony Biosciences Holdings has disclosed Non-Current Debt across 8 years of filings, most recently posting $138.8 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $138.8 million, down 12.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $138.8 million (down 12.24% YoY), and the FY2025 annual result was $143.7 million, down 11.87% from the prior year.
• Non-Current Debt came in at $138.8 million for Q1 2026 at Harmony Biosciences Holdings, down from $143.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $189.9 million in Q1 2022 to a low of $138.8 million in Q1 2026.
• The 5-year median for Non-Current Debt is $175.0 million (2024), against an average of $170.9 million.
• Across the five-year window, Non-Current Debt retreated 0.18% in 2022 and declined 12.24% in 2026, its largest moves.
• Harmony Biosciences Holdings' Non-Current Debt stood at $189.6 million in 2022, then decreased by 5.84% to $178.6 million in 2023, then slipped by 8.71% to $163.0 million in 2024, then decreased by 11.87% to $143.7 million in 2025, then slipped by 3.38% to $138.8 million in 2026.
• The last three Non-Current Debt figures came in at $138.8 million (Q1 2026), $143.7 million (Q4 2025), and $148.5 million (Q3 2025), per Business Quant data.